The Life Sciences practice of Deloitte & Touche USA LLP is delighted to be a participating cosponsor of UC Berkeley's 2008 BioExec Institute. The BioExec Institute is an internationally renowned executive program delivered by leaders in the industry to director and vice president-level management who are searching for the keys to managing business trade-offs within a highly regulated and competitive industry. Below, learn more about the latest issues and trends that are playing a critical role in shaping the landscape of this industry.

A Race Worth Running Scientific advances have made possible the impossible. Personalized medicine is now a reality, but how realistic are the economics of this breakthrough? As discoveries outpace dollars, new opportunities and challenges arise for stakeholders across the entire life sciences value chain. Subscribe to Life Sciences Research

Stay Connected Subscribe to receive the latest insights and ideas from our Life Sciences industry practice — available with the click of your mouse! Dbriefs Webcasts Podcasts New Horizons  Big pharma and biotech companies are beginning to seek outsourcing alliances for strategic purposes, further shrinking the borders. Learn to navigate the pitfalls of this expansion to gain the most from these new markets.   Readjust the Lens Strategy reinvention and innovative approaches are necessary to remain competitive and financially viable in this age of change. Manufacturing New Opportunities Explore innovative resources and seek the latest production modelsmto revolutionize business. Risk Roulette Know your odds at this high-stakes game. The Risk Intelligent Life Sciences Company FDA Shifts to Risk Management Global Security Study: Perspectives for Life Sciences Is Convergence the Key? As the paths of biotech and pharma companies meet, both stand to benefit. Don’t Fall Prey to the Unexpected Through the course of their existence, biotech companies encounter many milestones that guide their path. Learn how to recognize these life events and be prepared to handle them effectively. Chart the Course Ahead  The genomic revolution’s push for personalization and the ways by which financial success is measured force biotechs to reexamine their course.